查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1840898

神經生物學生物標記市場（按生物標記類型、技術平台、應用和最終用戶）—2025-2032 年全球預測

Neurological Biomarkers Market by Biomarker Type, Technology Platform, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年神經生物學標記物市場將成長至 301.5 億美元，複合年成長率為 14.45%。

主要市場統計數據
基準年2024年 102.4億美元
預計2025年 117.4億美元
預測年份：2032年 301.5億美元
複合年成長率（%） 14.45%

神經生物標記的權威介紹，闡述科學進步、臨床效用、商業化路徑以及對相關人員的策略意義

神經系統生物標記正在改變臨床醫生和科學家處理複雜中樞神經系統疾病的方式，使其從概念性目標轉變為臨床開發、診斷工作流程和轉化研究中的可操作要素。這些可測量的生物指標涵蓋分子特徵、成像模式和功能讀數，兩者結合，可實現早期檢測、精細的患者分層以及對治療反應的客觀監測。因此，臨床、商業和監管相關人員擴大將生物標記視為降低臨床試驗變異性和提高藥物開發信噪比的重要工具。

檢測靈敏度、計算分析和高解析度成像方面的進步正在加速候選標記物向經驗證的臨床應用的轉化。互補的驅動力包括：對精準神經病學的日益關注、支付方對循證診斷的興趣，以及學術聯盟與產業日益深化的合作。這些力量共同重塑了開發路徑、投資重點和應用曲線，為尋求引領生物標記解決方案的公司創造了機會和商業挑戰。本介紹描繪了一幅更廣闊的圖景，強調了科學與商業化之間的相互關係，並展望了生物標記物將如何影響研究和臨床護理領域的策略決策。

積極整合技術、監管環境和護理服務方面的變化，重新定義神經生物標記格局和價值鏈

隨著技術的融合、監管環境的日益成熟以及護理模式的不斷發展，神經系統生物標記領域正在發生變化。高通量分子平台如今正與多模態成像和高精度蛋白質體學相輔相成，使疾病表徵的精細度達到了前所未有的水平。同時，先進的機器學習和聯合分析等計算方法正在從異質資料集中提取臨床可操作的訊號，加快生物標記檢驗週期，並實現自適應試驗設計。

法律規範滿足了對強力證據標準的需求，同時為合格的生物標記和伴隨診斷提供了簡化的途徑。支付者和醫療系統更加重視診斷價值和長期健康經濟效益，並激勵那些能夠顯著改變患者管理或降低下游成本的生物標記。此外，透過遠端監控和數位終端實現臨床研究的去中心化，拓寬了生物標記收集和應用的範圍，技術供應商、學術中心和臨床網路之間的合作在擴大證據產生方面發揮核心獎勵。總而言之，這些轉變正在將生物標記從孤立的研究產品轉變為治療生態系統的整合組成部分，影響著開發時間表、資金配置和跨部門合作。

2025 年美國關稅對整個生物標記生態系統的採購、創新途徑和業務連續性的累積影響的策略分析

2025年美國關稅對整個神經生物標記生態系統的供應鏈、籌資策略和成本結構產生了複合影響。依賴進口的領域，例如高階成像硬體和專用檢測試劑，面臨直接的價格壓力，迫使研究機構和臨床實驗室重新評估資本採購計畫和消耗品庫存。這些發展趨勢強化了庫存管理、合約重新談判以及早期供應商多元化對於依賴進口設備和單一來源試劑的研究機構的重要性。

累積的後果不僅影響了直接採購成本，也影響了計劃優先順序和營運順序。擁有強大國內製造夥伴關係和垂直整合供應鏈的組織能夠緩解短期中斷，並維持關鍵研究的連續性。相反，規模較小的研究機構和一些委外研發機構面臨採購延遲，影響了註冊時間和分析吞吐量。為此，相關人員加快了本地化供應的步伐，包括技術轉移協議、與國內製造商的共同開發契約以及為供應商提供確定性的長期採購合約。

重要的是，這種政策環境也引發了不同技術領域的策略性再平衡。資本密集型影像處理平台通常需要集中投資和簽訂專業服務契約，因此採購週期更長，且對總擁有成本 (TCO) 的考慮也更高。相反，進口依賴程度較低的模組化和分散式技術，例如某些分子平台和可攜式診斷工具，由於其相對韌性而吸引了更大的關注。因此，關稅引發了策略性採購最佳化，加速了關鍵部件的在地化，並重新強調了供應鏈可視性和情境規劃。

細分主導的深入洞察，展示生物標記類別、平台選擇、應用和最終用戶如何相互作用以形成發展策略和採取路徑

細分洞察揭示了微妙的採用模式和技術發展軌蹟的差異，可以幫助開發者、臨床醫生和投資者確定優先順序。細胞標記物和蛋白質特徵通常從發現階段過渡到檢測方法最佳化階段；基因標記物為持續的患者分層提供了機會，尤其是在存在遺傳風險或變異引導療法的情況下；影像生物標記物為疾病進展提供空間和時間背景；代謝物測量可以提供敏感的生化變化指標。每種生物標記物都面臨不同的驗證挑戰、樣本處理要求以及與臨床工作流程的整合點。

這些生物標記所依賴的技術平台決定了可行性、通量和可解釋性。酵素結合免疫吸附檢測法等成熟的免疫測量法仍然是蛋白質定量的基礎，而質譜法則為蛋白質組學和代謝體學學分析提供了高特異性。次世代定序，包括 RNA 定序、標靶重定序和全基因組定序方法，已發展成為重要的基因研究平台，支持發現和診斷應用。聚合酵素鏈鎖反應繼續提供快速靈敏的核酸檢測，而電腦斷層掃描、功能性近紅外線光譜、磁振造影和正子斷層掃描等成像技術則提供解剖和功能表現型分析，這通常對於分子觀察的背景分析至關重要。

應用涵蓋診斷、藥物開發、縱向監測、預後建模和基礎研究，每種應用都有不同的性能標準和監管要求。最終用戶包括：促進大規模研究和檢測驗證的受託研究機構、將標記物轉化為臨床報告的診斷實驗室、在照護端應用生物標記物的醫院和診所、採用標記物降低開發項目風險的製藥和生物技術公司，以及推動發現和早期驗證的研究機構。了解每個細分軸如何相互作用，對於制定切合實際的產品藍圖和夥伴關係策略至關重要。

全面的區域概述，介紹美洲、歐洲、中東和非洲以及亞太地區的結構、監管和投資差異如何影響生物標記開發和商業化結果

區域動態對神經系統生物標記的監管途徑、投資流和應用曲線有顯著的影響，不同地區的優勢和挑戰也各不相同。在美洲，成熟的研究基礎設施、創投和公共資金籌措管道以及主要的臨床試驗網路正在加速轉化醫學的發展。該地區集中了專業的研究中心，並以支付主導，強調臨床效用的證明，這促進了診斷技術和伴隨標誌物的快速試點應用，同時也吸引了能夠將有前景的技術推廣到多中心研究的夥伴關係。

歐洲、中東和非洲地區擁有複雜的管理體制和醫療保健服務模式，這些都影響著生物標記的部署。儘管中東和非洲市場的基礎設施成熟度參差不齊，但精準醫療能力的投資正在迅速成長。在全部區域，協調工作和協作平台對於實現數據共用和建立可互通的生物標記鑑定標準正變得越來越重要。

在亞太地區，快速發展的臨床研究能力、公共和私人領域對生物技術的大量投資以及龐大的患者群體，為可擴展的檢驗和真實世界數據生成提供了重要機會。該地區的多個市場正在積極投資本地製造和數位健康平台，這可以加速分散式生物標記部署，並實現創新的臨床實驗設計。這些區域特徵的結合可以為場地選擇、夥伴關係模式和監管參與等方面的策略選擇提供參考，從而最佳化證據生成和商業化路徑。

深入研究平台領導、策略夥伴關係、監管參與和商業化模式如何決定生物標記生態系統中公司之間的競爭定位

公司層級的動態凸顯出這樣一種格局：技術領先、策略夥伴關係和平台廣度決定了競爭地位。儀器製造商和平台提供者透過精度、擴充性和與分析生態系統的整合來實現差異化，而試劑和耗材供應商則注重批次間一致性、供應鏈可靠性和檢測標準化。診斷開發人員專注於臨床驗證和付款人參與，以將分析性能轉化為臨床應用；製藥公司也擴大將生物標記納入研究設計中，以支持標靶治療並最佳化患者選擇。

公司、學術中心和臨床網路之間的策略合作正在不斷推進，以實現對生物樣本庫、縱向隊列和檢驗終點的共用存取。有些公司追求垂直整合以控制價值鏈中的關鍵點，而有些公司則優先考慮開放平台和資料互通性，以加速合作夥伴的吸收。在整個生態系統中，競爭差異化是透過投資監管科學來降低核准途徑風險，建立強大的真實世界證據項目來證明臨床效用，以及部署將診斷報銷與已證實的健康結果相結合的商業模式來實現的。隨著生物標記從研究工具轉向常規臨床應用，這些公司層級的策略共同影響誰能獲得價值。

為領導者提供清晰、實用的建議，以建立供應彈性、加速驗證、儘早與監管機構接觸，並透過永續的經營模式將生物標記商業化

產業領導者應採取多管齊下的策略，在短期業務韌性與長期技術領先之間取得平衡。首先，透過供應商多元化、本地製造夥伴關係和長期採購協議來增強供應鏈韌性，將降低貿易中斷和成本波動的風險。其次，投資分析基礎設施和管理縱向資料集，將增強異質人群中生物標記檢驗的能力，並支持付款人就臨床效用和價值進行對話。

研發領導者還應優先在研發早期與監管機構合作，以確保證據策略與資格認證路徑一致，並促進臨床應用。組成競爭前驗證聯盟並參與標準化計劃可以擴大認可並減少重複工作。從商業性角度來看，設計靈活的經營模式（從付費檢驗到基於結果的報銷試點）可以加速市場准入，同時與付款人和醫療保健提供者共用研發風險。最後，培養一支融合分子科學、影像分析、監管事務和衛生經濟學的多學科人才隊伍，對於將技術創新轉化為持續的臨床影響至關重要。這些步驟共同構成了將科學進步轉化為可擴展的臨床解決方案和永續商業成果的可行藍圖。

透明的混合方法調查方法結合了系統性的次要研究、一手專家訪談和嚴格的資料三角測量，確保了可靠且檢驗的見解

研究途徑將系統性的二手資料研究與一手相關人員、檢驗主任、臨床試驗協調員和供應鏈高管進行結構化訪談，以了解現實世界的限制因素、應用促進因素和營運權衡。

我們進行了資料三角檢驗，以協調資訊來源差異，並揭示在關鍵問題（例如檢測標準化、監管途徑和商業化障礙）上的共識和分歧。品管程序包括訪談記錄的雙盲檢驗、技術規範的交叉引用以及獨立專家對分析假設的檢驗。調查方法的局限性與新興生物標記已發表數據的差異性以及區域報告差異有關。這種混合方法設計優先考慮可重複性和可追溯性，同時捕捉可操作決策所需的細微觀點。

結論性綜合強調了科學進步、營運彈性和共同檢驗的整合如何實現臨床應用和策略價值創造

技術創新、不斷演變的法規以及不斷變化的商業性獎勵，正在促成更精準的診斷和治療策略。轉化醫學領域的進展最為強勁，當高保真測量平台與強大的分析框架和協作證據生成模型相結合時，就能產生可用於患者選擇、監測和預後的可靠生物標記。同時，供應鏈薄弱、驗證標準差異以及區域監管複雜性等實際障礙，仍在持續影響生物標記的採用時間表和策略選擇。

那些優先考慮互通性、投資於不同隊列驗證並建立彈性運作模式的組織將能夠更好地將生物標記的前景轉化為可衡量的臨床和商業性成果。透過使產品開發與付款人需求保持一致、積極與監管機構合作以及建立策略夥伴關係關係，相關人員可以充分發揮生物標記在改善患者照護和降低治療開發風險方面的潛力。這項結論強調，需要採取有計劃、協作且資源充足的方法，將科學進步轉化為日常臨床實踐。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 在多中心臨床試驗中整合血漿磷酸化Tau 217 檢測以早期檢測阿茲海默症
  • 超靈敏單分子陣列技術的出現，可量化血液樣本中的神經絲輕鏈水平
  • 開發結合澱粉樣BETA蛋白和Tau異構體的多重腦脊髓液生物標記組用於失智症的鑑別診斷
  • 推出免疫檢測平台，可遠端監測帕金森氏症患者的生物標記變化
  • 擴展人工智慧演算法以解釋神經退化性疾病早期檢測中的複雜生物標記數據模式
  • 基於血液的發炎生物標記檢測在多發性硬化症治療試驗中追蹤小膠質細胞活化的進展
  • 擴大監管支持途徑，以核准用於藥物開發和個人化醫療應用的新型神經生物標記

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第 8 章神經生物標記市場（按生物標記類型）

  • 蜂巢
  • 遺傳
  • 影像學
  • 代謝物
  • 蛋白質

9. 神經生物標記市場技術平台

  • 酵素結合免疫吸附試驗
  • 影像技術
    • 電腦斷層掃描
    • 功能近紅外線光譜
    • 磁振造影
    • 正子斷層掃描
  • 質譜法
  • 次世代定序
    • RNA定序
    • 標靶定序
    • 全基因組定序
  • 聚合酵素鏈鎖反應

第 10 章神經生物標記物市場（按應用）

  • 診斷
  • 藥物開發
  • 監控
  • 預後
  • 調查

第 11 章神經生物標記物市場（按最終用戶）

  • 合約研究組織
  • 診斷實驗室
  • 醫院和診所
  • 製藥和生物技術公司
  • 研究機構

第12章神經生物標記市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章神經生物標記市場（按類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 神經生物標記市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Danaher Corporation
    • Thermo Fisher Scientific Inc.
    • Roche Holding AG
    • Siemens Healthineers AG
    • Abbott Laboratories
    • Bio-Rad Laboratories, Inc.
    • PerkinElmer, Inc.
    • Quanterix Corporation
    • Meso Scale Diagnostics, LLC
    • Fujirebio Diagnostics, Inc.
Product Code: MRR-AD36CD897EE7

The Neurological Biomarkers Market is projected to grow by USD 30.15 billion at a CAGR of 14.45% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 10.24 billion
Estimated Year [2025] USD 11.74 billion
Forecast Year [2032] USD 30.15 billion
CAGR (%) 14.45%

An authoritative introduction to neurological biomarkers that frames scientific advances, clinical utility, commercialization pathways, and strategic implications for stakeholders

Neurological biomarkers have moved from conceptual targets to operational elements in clinical development, diagnostic workflows, and translational research, altering how clinicians and scientists approach complex central nervous system disorders. These measurable biological indicators span molecular signatures, imaging patterns, and functional readouts that together enable earlier detection, refined patient stratification, and objective monitoring of therapeutic response. As a result, stakeholders across clinical, commercial, and regulatory domains increasingly view biomarkers as indispensable tools for reducing trial variability and improving the signal-to-noise ratio in drug development.

Advances in assay sensitivity, computational analytics, and high-resolution imaging have accelerated the translation of candidate markers into validated clinical applications. Complementary drivers include a stronger emphasis on precision neurology, payer interest in evidence-based diagnostics, and deeper collaborations between academic consortia and industry. Taken together, these dynamics are reshaping development pathways, investment priorities, and adoption curves, creating both opportunities and operational challenges for organizations seeking to lead in biomarker-enabled solutions. This introduction frames the broader landscape, clarifies the interplay between science and commercialization, and sets expectations for how biomarkers will influence strategic decision-making across research and clinical care.

A forward-looking synthesis of converging technological, regulatory, and care delivery shifts that are redefining the neurological biomarker landscape and value chain

The landscape for neurological biomarkers is experiencing transformative shifts driven by converging technologies, regulatory maturation, and evolving care models. High-throughput molecular platforms now complement multimodal imaging and high-precision proteomics, enabling a level of granularity in disease characterization that was previously unattainable. At the same time, computational methods such as advanced machine learning and federated analytics are extracting clinically actionable signals from heterogeneous datasets, accelerating biomarker validation cycles and enabling adaptive trial designs.

Regulatory frameworks are responding to the need for robust evidentiary standards while also offering streamlined pathways for qualified biomarkers and companion diagnostics. Payers and health systems are placing greater emphasis on diagnostic value and long-term health economic outcomes, incentivizing biomarkers that demonstrably alter patient management or reduce downstream costs. Additionally, the decentralization of clinical research through remote monitoring and digital endpoints is broadening the contexts in which biomarkers are collected and applied, and partnerships between technology vendors, academic centers, and clinical networks are becoming central to scaling evidence generation. Collectively, these shifts are transforming biomarkers from isolated research outputs into integrated components of therapeutic ecosystems, with implications for development timelines, capital allocation, and cross-sector collaboration.

A strategic analysis of the cumulative implications from United States tariff actions in 2025 on procurement, innovation pathways, and operational continuity across the biomarker ecosystem

Tariff measures introduced in the United States in 2025 have had a compound influence on supply chains, procurement strategies, and cost structures across the neurological biomarker ecosystem. Import-dependent segments such as high-end imaging hardware and specialized assay reagents experienced immediate pricing pressures, prompting research institutions and clinical laboratories to reassess capital procurement timelines and consumables inventories. These dynamics amplified the importance of inventory management, contract renegotiation, and early-stage supplier diversification for organizations that rely on imported instrumentation or single-source reagents.

The cumulative consequences extended beyond direct procurement costs to affect project prioritization and operational cadence. Organizations with robust domestic manufacturing partnerships or vertically integrated supply chains were able to mitigate short-term disruptions and preserve continuity for critical studies. Conversely, smaller research entities and some contract research organizations faced procurement delays that affected enrollment timelines and analytical throughput. In response, stakeholders accelerated initiatives to localize supply, including technology transfer agreements, co-development contracts with domestic manufacturers, and longer-term purchasing commitments that provided certainty to suppliers.

Importantly, the policy environment also triggered strategic rebalancing among technology classes. Capital-intensive imaging platforms, which typically require centralized investments and specialized service contracts, experienced longer procurement cycles and increased total cost of ownership considerations. Conversely, modular and decentralized technologies with lower import dependence, including certain molecular platforms and portable diagnostic tools, garnered elevated interest for their relative resilience. The tariffs therefore acted as a catalyst for strategic procurement optimization, accelerated localization of critical components, and renewed emphasis on supply chain visibility and scenario planning.

Detailed segmentation-driven insights illustrating how biomarker classes, platform choices, applications, and end-users interact to shape development strategies and adoption pathways

Segmentation insights reveal nuanced adoption patterns and differential technology trajectories that inform prioritization for developers, clinicians, and investors. Biomarker types vary in their translational pathways: cellular markers and protein signatures often move from discovery to assay optimization, genetic markers provide durable patient stratification opportunities particularly where heritable risk or variant-guided therapies exist, imaging biomarkers deliver spatial and temporal context for disease progression, and metabolite measures can offer sensitive indicators of biochemical shifts. Each class presents distinct validation challenges, sample handling requirements, and integration points with clinical workflows.

Technology platforms underpin these biomarker types and shape feasibility, throughput, and interpretability. Established immunoassays such as enzyme-linked immunosorbent assay remain fundamental for protein quantification, while mass spectrometry offers high specificity for proteomic and metabolomic profiling. Next-generation sequencing has matured into a critical platform for genetic interrogation, encompassing RNA sequencing, targeted resequencing, and whole genome sequencing approaches that support both discovery and diagnostic applications. Polymerase chain reaction methods continue to provide rapid and sensitive nucleic acid detection, and imaging techniques-including computed tomography, functional near-infrared spectroscopy, magnetic resonance imaging, and positron emission tomography-supply anatomical and functional phenotyping that is often essential to contextualize molecular findings.

Applications span diagnostics, drug development, longitudinal monitoring, prognostic modeling, and basic research, each imposing different performance criteria and regulatory expectations. End users include contract research organizations that facilitate large-scale studies and assay validation, diagnostic laboratories that translate markers into clinical reports, hospitals and clinics that implement biomarkers at the point of care, pharmaceutical and biotechnology companies that employ markers to de-risk development programs, and research institutes that drive discovery and early validation. Understanding how each segmentation axis interacts is critical for realistic product roadmaps and partnership strategies, since success depends on aligning platform capabilities with the intended application and end-user environment.

A comprehensive regional synthesis of how structural, regulatory, and investment differences across the Americas, Europe Middle East & Africa, and Asia-Pacific shape biomarker development and commercialization outcomes

Regional dynamics exert a profound influence over regulatory pathways, investment flows, and adoption curves for neurological biomarkers, with distinct strengths and challenges across geographies. In the Americas, mature research infrastructures, deep venture and public funding channels, and leading clinical trial networks accelerate translational momentum. The region's concentration of specialized centers and payer-driven emphasis on demonstrable clinical utility foster rapid pilot adoption for diagnostics and companion markers, while also attracting partnerships that can scale promising technologies into multi-center studies.

The Europe, Middle East & Africa region presents a complex mosaic of regulatory regimes and healthcare delivery models that influence biomarker deployment. European markets often benefit from coordinated regulatory science initiatives and cross-border research consortia that support multi-national validation studies, whereas Middle Eastern and African markets display variable infrastructure maturity but rapidly expanding investment in precision medicine capabilities. Across the region, harmonization efforts and collaborative platforms are increasingly important to enable data sharing and to create interoperable standards for biomarker qualification.

In the Asia-Pacific region, fast-growing clinical research capacity, substantial public and private investment in biotechnology, and large patient populations offer significant opportunities for scalable validation and real-world data generation. Several markets within the region are investing aggressively in local manufacturing and digital health platforms, which can accelerate deployment of decentralized biomarkers and enable innovative trial designs. Combined, these regional characteristics inform strategic choices about site selection, partnership models, and regulatory engagement to optimize evidence generation and commercialization pathways.

An incisive look at how platform leadership, strategic partnerships, regulatory engagement, and commercialization models determine competitive positioning among firms in the biomarker ecosystem

Company-level dynamics underscore a landscape where technological leadership, strategic partnerships, and platform breadth determine competitive position. Instrument manufacturers and platform providers continue to differentiate through accuracy, scalability, and integration with analytic ecosystems, while reagent and consumables suppliers focus on lot-to-lot consistency, supply chain reliability, and assay standardization. Diagnostic developers are concentrating on clinical validation and payer engagement to translate analytical performance into clinical adoption, and pharmaceutical companies are increasingly embedding biomarkers into trial design to support targeted therapies and to optimize patient selection.

Strategic collaborations between industry, academic centers, and clinical networks are a recurrent theme, enabling shared access to biobanks, longitudinal cohorts, and validated endpoints. Some firms are pursuing vertical integration to control critical points in the value chain, whereas others prioritize open platforms and data interoperability to accelerate partner uptake. Across the ecosystem, competitive differentiation is achieved by investing in regulatory science to de-risk approval pathways, building robust real-world evidence programs that demonstrate clinical utility, and deploying commercial models that align diagnostic reimbursement with demonstrated health outcomes. These company-level strategies collectively influence who captures value as biomarkers transition from research tools into routine clinical applications.

Clear and practical recommendations for leaders to build supply resilience, accelerate validation, engage regulators early, and commercialize biomarkers with sustainable business models

Industry leaders should adopt a multifaceted strategy that balances near-term operational resilience with long-term technological leadership. First, strengthening supply chain resilience through supplier diversification, localized manufacturing partnerships, and longer-term procurement contracts reduces exposure to trade disruptions and cost volatility. Second, investing in analytic infrastructure and curated longitudinal datasets enhances the ability to validate biomarkers across heterogeneous populations and supports payer conversations about clinical utility and value.

Leaders should also prioritize regulatory engagement early in development to align evidentiary strategies with qualification pathways and to expedite clinical adoption. Forging consortia for precompetitive validation and participating in standards initiatives will broaden acceptance and reduce duplication of effort. From a commercial perspective, designing flexible business models-ranging from fee-for-service validation to outcome-based reimbursement pilots-can accelerate market access while sharing development risk with payers and providers. Finally, cultivating cross-disciplinary talent that blends molecular science, imaging analytics, regulatory affairs, and health economics will be critical to translate technical innovation into durable clinical impact. Together, these steps form an actionable roadmap for converting scientific advances into scalable clinical solutions and sustainable business outcomes.

A transparent mixed-methods research methodology combining systematic secondary review, expert primary interviews, and rigorous data triangulation to ensure robust and verifiable insights

The research approach combines systematic secondary review, primary stakeholder engagement, and iterative evidence synthesis to ensure balanced and verifiable insights. Secondary research encompassed peer-reviewed literature, regulatory guidance documents, technical white papers, and industry disclosures to map technology capabilities, validation frameworks, and clinical integration models. Primary research included structured interviews with key opinion leaders, laboratory directors, clinical trial coordinators, and supply chain executives to capture real-world constraints, adoption drivers, and operational trade-offs.

Data triangulation was used to reconcile findings across sources and to highlight consensus versus divergence on critical issues such as assay standardization, regulatory pathways, and commercialization barriers. Quality control procedures included double-blind verification of interview transcripts, cross-referencing of technical specifications, and validation of analytic assumptions with independent domain experts. Limitations of the methodology relate to variability in publicly available data for emerging biomarkers and differential reporting across regions; where gaps existed, qualitative expert judgment was used and transparently annotated. This mixed-methods design prioritizes reproducibility and traceability while capturing the nuanced perspectives necessary for actionable decision-making.

A conclusive synthesis emphasizing where scientific advances, operational resilience, and collaborative validation converge to enable clinical adoption and strategic value creation

The cumulative examination of neurological biomarkers reveals an ecosystem in transition: technological innovation, regulatory evolution, and shifting commercial incentives are collectively enabling more precise diagnostic and therapeutic strategies. Translational progress is strongest where high-fidelity measurement platforms intersect with robust analytic frameworks and collaborative evidence-generation models, producing biomarkers that can be confidently used for patient selection, monitoring, and prognostication. At the same time, practical impediments such as supply chain fragility, heterogeneity in validation standards, and regional regulatory complexity continue to shape adoption timelines and strategic choices.

Organizations that prioritize interoperability, invest in validation across diverse cohorts, and build resilient operational models will be well-positioned to convert biomarker promise into measurable clinical and commercial outcomes. By aligning product development with payer needs, engaging regulators proactively, and fostering strategic partnerships, stakeholders can realize the full potential of biomarkers to improve patient care and to de-risk therapeutic development. The conclusion reinforces the need for deliberate, collaborative, and well-resourced approaches to translate scientific advances into routine clinical practice.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of plasma phosphorylated tau 217 assays for early Alzheimer's detection in multicenter clinical studies
  • 5.2. Emergence of ultrasensitive single-molecule array technology for quantifying neurofilament light chain levels in blood samples
  • 5.3. Development of multiplex cerebrospinal fluid biomarker panels combining amyloid beta and tau isoforms for differential dementia diagnosis
  • 5.4. Adoption of digital immunoassay platforms enabling remote monitoring of biomarker fluctuations in Parkinson's disease patients
  • 5.5. Expansion of artificial intelligence algorithms to interpret complex biomarker data patterns in early detection of neurodegenerative disorders
  • 5.6. Advancements in blood-based inflammatory biomarker assays to track microglial activation in multiple sclerosis therapeutic trials
  • 5.7. Growth of regulatory support pathways for novel neurological biomarker clearance in drug development and personalized medicine applications

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Neurological Biomarkers Market, by Biomarker Type

  • 8.1. Cellular
  • 8.2. Genetic
  • 8.3. Imaging
  • 8.4. Metabolite
  • 8.5. Protein

9. Neurological Biomarkers Market, by Technology Platform

  • 9.1. Enzyme-Linked Immunosorbent Assay
  • 9.2. Imaging Techniques
    • 9.2.1. Computed Tomography
    • 9.2.2. Functional Near-Infrared Spectroscopy
    • 9.2.3. Magnetic Resonance Imaging
    • 9.2.4. Positron Emission Tomography
  • 9.3. Mass Spectrometry
  • 9.4. Next-Generation Sequencing
    • 9.4.1. RNA Sequencing
    • 9.4.2. Targeted Resequencing
    • 9.4.3. Whole Genome Sequencing
  • 9.5. Polymerase Chain Reaction

10. Neurological Biomarkers Market, by Application

  • 10.1. Diagnostics
  • 10.2. Drug Development
  • 10.3. Monitoring
  • 10.4. Prognostics
  • 10.5. Research

11. Neurological Biomarkers Market, by End User

  • 11.1. Contract Research Organizations
  • 11.2. Diagnostic Laboratories
  • 11.3. Hospitals & Clinics
  • 11.4. Pharmaceutical & Biotechnology Companies
  • 11.5. Research Institutes

12. Neurological Biomarkers Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Neurological Biomarkers Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Neurological Biomarkers Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Danaher Corporation
    • 15.3.2. Thermo Fisher Scientific Inc.
    • 15.3.3. Roche Holding AG
    • 15.3.4. Siemens Healthineers AG
    • 15.3.5. Abbott Laboratories
    • 15.3.6. Bio-Rad Laboratories, Inc.
    • 15.3.7. PerkinElmer, Inc.
    • 15.3.8. Quanterix Corporation
    • 15.3.9. Meso Scale Diagnostics, LLC
    • 15.3.10. Fujirebio Diagnostics, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NEUROLOGICAL BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. NEUROLOGICAL BIOMARKERS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. NEUROLOGICAL BIOMARKERS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY CELLULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY CELLULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY CELLULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY CELLULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY CELLULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY CELLULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GENETIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GENETIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GENETIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GENETIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GENETIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GENETIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY METABOLITE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY METABOLITE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY METABOLITE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY METABOLITE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY METABOLITE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY METABOLITE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROTEIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROTEIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROTEIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROTEIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROTEIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROTEIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY FUNCTIONAL NEAR-INFRARED SPECTROSCOPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY FUNCTIONAL NEAR-INFRARED SPECTROSCOPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY FUNCTIONAL NEAR-INFRARED SPECTROSCOPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY FUNCTIONAL NEAR-INFRARED SPECTROSCOPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY FUNCTIONAL NEAR-INFRARED SPECTROSCOPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY FUNCTIONAL NEAR-INFRARED SPECTROSCOPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY RNA SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY RNA SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY RNA SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY RNA SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY RNA SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY RNA SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TARGETED RESEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TARGETED RESEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TARGETED RESEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TARGETED RESEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TARGETED RESEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TARGETED RESEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY DRUG DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY DRUG DEVELOPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY DRUG DEVELOPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY DRUG DEVELOPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY DRUG DEVELOPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY DRUG DEVELOPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY RESEARCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY RESEARCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY RESEARCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. NORTH AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 198. NORTH AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 200. NORTH AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 204. NORTH AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 206. NORTH AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. LATIN AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 212. LATIN AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 214. LATIN AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 216. LATIN AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 218. LATIN AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 220. LATIN AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 222. LATIN AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. MIDDLE EAST NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. MIDDLE EAST NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 256. MIDDLE EAST NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 258. MIDDLE EAST NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 259. MIDDLE EAST NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 260. MIDDLE EAST NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 261. MIDDLE EAST NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 262. MIDDLE EAST NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 264. MIDDLE EAST NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 265. AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
  • TABLE 269. AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 270. AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 271. AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 272. AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 273. AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 274. AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 275. AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 276. AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 277. AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 278. AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 280. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 281. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 282. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
  • TABLE 283. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 284. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 286. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 287. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 288. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 289. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 290. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 291. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 292. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 295. ASEAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 296. ASEAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 297. ASEAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. ASEAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. ASEAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 300. ASEAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 301. ASEAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 302. ASEAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2025-2032 (USD MILLION)
  • TABLE 303. ASEAN NEUROLOGICAL